Company Overview of Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...
12625 High Bluff Drive
San Diego, CA 92130
Founded in 1981
Key Executives for Tamir Biotechnology, Inc.
Chief Executive Officer, President, Secretary, and Director
Chief Financial Officer and Secretary
Chairman of the Thoracic Cancer Advisory Board
Special Advisor to Chief Executive Officer
Compensation as of Fiscal Year 2016.
Tamir Biotechnology, Inc. Key Developments
Tamir Biotechnology Announces Results from Pre-Clinical Investigational Study at Institute of Antiviral Research
Feb 22 16
Tamir Biotechnology announced results from a pre-clinical investigational study at the Institute of Antiviral Research at Utah State University. The study evaluated the anti-viral activity of ranpirnase in an established cell model of Zika virus infection. Overall, the study revealed that ranpirnase was active in blocking Zika virus relative to a control. In previous cell based studies, ranpirnase exhibited no cytotoxic effects at therapeutically effective dose levels. The clinical work with the Zika virus builds on years of work with other virally-caused pathologies such as Ebola. Results from a recent NIH-sponsored study on the Ebola virus gave 100% survival in ranpirnase-treated animals administered with therapeutic levels of the drug post-infection. The virus was undetectable in the serum of ranpirnase-treated mice at eight days post-infection. The company's clinical program is led by their phase II investigation of a topical formulation of ranpirnase in the treatment of HPV genital warts. This study is expected to begin enrollment in South America in February 2016. There are an estimated 14 million new and recurrent HPV infections per year in the US alone and the global HPV market is estimated to be over USD 2 billion in 2020. Ranpirnase for injection has been safely administered to over 1,000 subjects in previous oncology clinical trials.
Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola
Apr 30 15
Tamir Biotechnology announced an update on its Ebola antiviral therapy program. One of Tamir's candidates, TMR004, is currently being evaluated and considered by a number of clinicians on the frontline of the battle against Ebola. The company also this week received additional data from its continued investigation into the anti-Ebola properties of TMR004. In a therapeutic pre-clinical mouse model conducted at the University of Texas Medical Branch, the drug was administered intraperitoneally at three dose levels to animals previously infected with the Ebola virus. TMR004 conferred a statistically definitive survival advantage relative to the control group. This finding was consistent with earlier investigations in which the US Army Medical Research Institute for Infectious Diseases showed that prophylactically administered TMR004 confers one of the high survival rates observed for experimental drugs in the fight against Ebola virus. More studies are planned for the immediate future in additional animal models of infection. TMR004, the company's candidate, has a rich legacy as a therapeutic agent. This type III RNase is able to inhibit viral replication through halting synthesis of viral protein without altering cellular constituents. It is noteworthy that since TMR004 degrades double stranded RNA produced by most viruses, it less likely that viruses will develop resistance despite the high mutation rates seen with pathogens like Ebola. A form of the drug, formerly known by the ONCONASE trademark and as "Onconase for injection", was previously evaluated by the US Food and Drug Administration for over twenty years in numerous clinical trials. Its safety was considered sufficient to permit administration to over 1,000 patients as part of its development against malignant mesothelioma.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 12, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries